Co-Diagnostics EBITDA per Employee
The EBITDA per Employee of Co-Diagnostics (CODX) as of Oct 9, 2026 is -272,029.15 USD. In the previous year, EBITDA per Employee was -336,556.61 USD — a change of -19.17% (higher).
Get this data via API
Financial Data API
EBITDA per Employee
-272,029.15USD
YoY
-19.17%
Last updated:
The Co-Diagnostics EBITDA per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA per Employee | YoY |
|---|---|---|
| -272,029.15USD | -19.17% | |
| -336,556.61USD | -6.68% | |
| -360,658.56USD | +61.39% | |
| -223,476.84USD | -155.38% | |
| 403,521.33USD | +10.93% | |
| 363,770.78USD | -795.01% | |
| -52,340.17USD | -1.11% | |
| -52,928.49USD | -7.76% | |
| -57,382.60USD | +300.43% | |
| -14,330.14USD | -14.52% | |
| -16,765.03USD | +88.21% | |
| -8,907.59USD | — |
Co-Diagnostics Stock analysis
Frequently Asked Questions about Co-Diagnostics stock
EBITDA per Employee of Co-Diagnostics is -272,029.15 USD in 2025.
EBITDA per Employee of Co-Diagnostics changed from -336,556.61 USD to -272,029.15 USD, representing a -19.17% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBITDA per Employee Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.
EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.
EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Co-Diagnostics historically and in real time.
Workforce — Co-Diagnostics
All Key Metrics — Co-Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth